Patient Survival Outcomes
Unrelated hematopoietic cell transplantation can result in improved survival outcomes when the patient's age, co-morbidities, disease, disease stage and transplant timing are favorable and a well-matched unrelated donor or cord blood unit is available.
The success of unrelated allogeneic transplantation for the selected diseases can be seen in patient survival outcomes on marrow.org as well as reference articles.
Patient Survival Outcomes Acute lymphoblastic leukemia (ALL)
Acute myelogenous leukemia (AML)
Chronic myelogenous leukemia (CML)
Non-Hodgkin's lymphoma (NHL)
Severe aplastic anemia (SAA)
Inherited immune system disorders
- Wiskott-Aldrich syndrome (WAS)
- Severe combined immunodeficiency (SCID)
Inherited metabolic disorders
- Hurler’s syndrome unrelated allogeneic outcomes (marrow.org)
- Cerebral X-linked adrenoleukodystrophy (ALD)
- Globoid-cell leukodystrophy (Krabbe's disease)
- Newborns transplanted before the onset of symptoms "maintained normal vision and hearing and normal cognitive development." [3]
Myelodysplastic syndromes (MDS)
References
1. Maris M, Sandmaier, B, Storer, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body radiation for relapsed and refractory mantle cell lymphoma.
Blood. 2004; 104 (12):3535-3542.
http://bloodjournal.hematologylibrary.org
/cgi/content/abstract/104/12/3535
- This article demonstrates the efficacy of non-myeoloablative allogeneic transplant for mantle cell lymphoma. "...nonmyeloablative conditioning allowed for successful allogeneic HCT in patients with advanced mantle cell lymphoma and was associated with a high response rate and low risk of relapse at 2 years."
2. Khouri I, Lee M, Saliba R, et al. Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma.
J Clin Oncology. 2003;21 (23):4407-4412.
http://jco.ascopubs.org/cgi/content/full/21/23/4407
- In this study, 17 of 18 patients achieved complete remission. "Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle disease."
3. Escolar ML, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's Disease.
N Engl J Med 2005; 352(20): 2069-2081.
http://content.nejm.org/cgi/content/abstract/352/20/2069
- According to this study, transplants using umbilical cord blood improve survival for babies born with Krabbe's disease. Newborns transplanted before the onset of symptoms "maintained normal vision and hearing and normal cognitive development," according to the researchers. Conversely, infants transplanted after becoming symptomatic experienced a higher rate of death and minimal neurological benefits. (Excerpt of summary from Advances in Transplantation newsletter marrow.org.)
|
E-mail a Friend
Print this Page